Skip to section navigation.
Skip to main page content.

Contact Details

Professor Laurence Patterson

<< Back


Professor Laurence Patterson

Professor of Drug Discovery and Institute Director
L.H.Patterson@bradford.ac.uk

Tel/ext: +44 (0) 1274 233226 (PA)
Fax: +44 (0) 1274 233234

Qualifications

PhD (London), BSc Hons (Hertfordshire)

Main research interests

  • Tumour-selective drug activation
  • The glycocalyx as a target for drug discovery
  • Modulators of integrin activity
  • Inhibitors of chemokines
  • Bioreductive activation of drugs in hypoxia tumours
  • Cytochromes P450 in tumours

Roles and Responsibilities

Major Grants

Postgraduate Student Supervision

  • Fatemah Al-Shammari (joint supervision with Dr Helen Sheldrake and Dr Steve Shnyder)
  • Hanadi Ahmedah (joint supervision with Dr Helen Sheldrake and Dr Steve Shnyder)
  • Manar Saleh Zraikat (joint supervisioon with Dr Helen Sheldrake, Dr Steve Shnyder and Dr Roger Phillips)
  • Abdulaziz Bin Saeedan (joint supervision with Dr Steve Shnyder and Dr Paul Loadman)
  • Adam Throup (joint supervision with Dr Helen Sheldrake)

Recent publications

  • Travica S, Pors K, Loadman PM, Shnyder SD, Johansson I, Alandas MN, Sheldrake HM, Mkrtchian S, Patterson LH, Ingelman-Sundberg M. Colon cancer-specific cytochrome P450 2W1 converts duocarmycin analogues into potent tumor cytotoxins.
    Clin Cancer Res. 2013 Apr 15. [Epub ahead of print] PubMed PMID: 23589180
  • Sutherland M, Gill JH, Loadman PM, Laye JP, Sheldrake HM, Illingworth NA, Alandas MN, Cooper PA, Searcey M, Pors K, Shnyder SD, Patterson LH. Antitumor activity of a duocarmycin analogue rationalized to be metabolically activated by
    cytochrome P450 1A1 in human transitional cell carcinoma of the bladder. Mol Cancer Ther. 2013 Jan;12(1):27-37. doi: 10.1158/1535-7163.MCT-12-0405. Epub 2012 Oct 1. PubMed PMID: 23033491
  • Falconer RA, Errington RJ, Shnyder SD, Smith PJ, Patterson LH. Polysialyltransferase: a new target in metastatic cancer. Curr Cancer Drug Targets. 2012 Oct;12(8):925-39. Review. PubMed PMID: 22463390
  • McMahon KM, Volpato M, Chi HY, Musiwaro P, Poterlowicz K, Peng Y, Scally AJ, Patterson LH, Phillips RM, Sutton CW. Characterization of changes in the proteome in different regions of 3D multicell tumor spheroids. J Proteome Res. 2012 May
    4;11(5):2863-75. doi: 10.1021/pr2012472. Epub 2012 Mar 30. PubMed PMID: 22416669
  • Pors K, Loadman PM, Shnyder SD, Sutherland M, Sheldrake HM, Guino M, Kiakos K, Hartley JA, Searcey M, Patterson LH. Modification of the duocarmycin pharmacophore enables CYP1A1 targeting for biological activity. Chem Commun (Camb). 2011 Nov 28;47(44):12062-4. doi: 10.1039/c1cc15638a. Epub 2011 Oct 14. PubMed PMID: 22002321
  • Veiga J.P., Cooper P.A., Pors K, Patterson L.H., Bibby M.C., Shnyder S.D. Use of the hollow fiber assay for the evaluation of DNA damaging agents. J Pharmacol Toxicol Methods. 2011 Nov-Dec;64(3):226-32. Epub 2011 Apr 30. PubMed PMID: 21569858
  • Vinader V, Al-Saraireh Y, Wiggins H.L., Rappoport J.Z., Shnyder S.D., Patterson L.H., Afarinkia K. An agarose spot chemotaxis assay for chemokine receptor antagonists. J Pharmacol Toxicol Methods. 2011 Nov-Dec;64(3):213-6. Epub 2011 Feb 1. PubMed PMID: 21292017
  • Atkinson J.M., Falconer R.A., Edwards D.R., Pennington C.J., Siller C.S., Shnyder S.D., Bibby M.C., Patterson L.H., Loadman P.M., Gill J.H. Development of a novel tumor-targeted vascular disrupting agent activated by membrane-type matrix metalloproteinases. Cancer Res. 2010 Sep 1;70(17):6902-12. Epub 2010 Jul 27 PubMed PMID: 20663911; PubMed Central PMCID: PMC2933508
  • Sutton C.W., Sutherland M, Shnyder S, Patterson L.H. Improved preparation and detection of cytochrome P450 isoforms using MS methods. Proteomics. 2010 Jan;10(2):327-31. PubMed PMID: 19902426
  • Seibert C, Davidson B.R., Fuller B.J., Patterson L.H., Griffiths W.J., Wang Y. Multiple-approaches to the identification and quantification of cytochromes P450 in human liver tissue by mass spectrometry. J Proteome Res. 2009 Apr;8(4):1672-81. PubMed PMID: 19714871; PubMed Central PMCID: PMC2939981
  • Sheldrake H.M., Patterson L.H. Function and antagonism of beta3 integrins in the development of cancer therapy. Curr Cancer Drug Targets. 2009 Jun;9(4):519-40. Review. PubMed PMID: 19519320
  • Abdallah Q.M., Phillips R.M., Johansson F, Helleday T, Cosentino L, Abdel-Rahman H, Etzad J, Wheelhouse R.T., Kiakos K, Bingham J.P., Hartley J.A., Patterson L.H., Pors K. Minor structural modifications to alchemix influence mechanism of action and pharmacological activity. Biochem Pharmacol. 2012 Jun 1;83(11):1514-22. Epub 2012 Mar 1. PubMed PMID: 22387433

Professional Society Memberships and Positions of Esteem

  • Honorary member of the Royal Pharmaceutical Society of Great Britain
  • Elected Fellow of the Royal Society of Chemistry
  • Guest Professor in Drug Discovery, TMMU, Chongqing, China
  • Honorary Professor in Drug Discovery, Southwestern University, Chongqing, China
  • British Association of Cancer Research
  • American Association for Cancer Research
  • Athenaeum (Pall Mall)
  • Member and panel member of the EPSRC peer review college 
  • Guest Editor for Current Topics in Pharmaceutical Design
  • International Editor Acta Academiae Medicinae Militaris Tertiae
  • RSC Team Innovation Award recipient 2012

<< Back